Amgen’s Latest Clinical Study: A New Front-Line Therapy for Lung Cancer?

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.

Amgen Inc. is conducting a Phase 3 clinical study titled ‘A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)’. The study aims to compare the progression-free survival and overall survival of patients treated with sotorasib combined with platinum doublet chemotherapy versus those treated with pembrolizumab with the same chemotherapy regimen. This research is significant as it targets patients with specific genetic markers, potentially leading to more effective personalized treatment options.

The interventions being tested include sotorasib, administered orally, in combination with carboplatin and pemetrexed, and pembrolizumab, administered intravenously, with the same chemotherapy agents. These treatments are designed to serve as front-line therapies for advanced nonsquamous non-small cell lung cancer.

The study is designed as an interventional, randomized, open-label trial with a parallel assignment. The primary purpose is treatment, and no masking is involved, allowing for direct comparison of the two treatment regimens.

The study began on November 16, 2023, with the last update submitted on August 20, 2025. These dates are crucial as they indicate the study’s current recruiting status and its progression towards completion, which is essential for investors tracking the development timeline.

This clinical update could influence Amgen’s stock performance positively, as successful outcomes may enhance the company’s competitive position in the oncology market. Investors should monitor this study’s progress, especially in the context of competing treatments for non-small cell lung cancer.

The study is ongoing, with further details available on the ClinicalTrials portal.